Malin : 2022 Interim Report Presentation

This document is personal to the recipient and has been prepared and issued by Malin Corporation plc (the "Company") incorporated and registered in Ireland under the Irish Companies Acts and is the responsibility of the Company. For the purposes of this notice, this presentation (the "Presentation") shall mean and include the slides, the oral presentation of the slides by the Company, hard copies of this document and any materials distributed at, or in connection with, that oral presentation. The slides are given in conjunction with an oral presentation and should not be taken out of context.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. Any decision to purchase securities of the Company must be made solely on the basis of the information gained from the recipients' own investigations and analysis of the Company. The information in this Presentation is subject to update, revision, and/or amendment without notice. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This Presentation is not a prospectus (or prospectus equivalent document). This Presentation does not contain "Inside Information" as that term is defined in the Market Abuse Regulation.

This Presentation is strictly private and confidential, is being supplied to you solely for your information and may not be copied, further distributed, published or reproduced in whole or in part, or otherwise disclosed. Failure to comply with these restrictions may constitute a violation of applicable securities laws and/or a criminal

offence. The content of this Presentation has not been approved by Euronext Dublin. This Presentation is being communicated for information purposes only.

No representation or warranty, express or implied, is given by or on behalf of the Company or its investee companies or any of such persons' advisors, or any of their respective parent or subsidiary undertakings, the subsidiary undertakings of any such parent undertakings or any of the directors, officers, employees of such person as to the fairness, accuracy or completeness of the contents of this Presentation, for the opinions contained in this Presentation or for any other statement made or purported to be made by any of them, or on behalf of them and no responsibility or liability is accepted by any person for such information or opinions. No person has been authorised to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorised. The contents of this Presentation are not to be construed as legal, financial or tax advice. No liability is accepted for any such information or opinions by the Company or its investee companies, or any of their respective directors, members, officers, employees, agents or advisers.

Nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. There is no obligation on any person to update this document, correct any inaccuracies which may become apparent or to publicly announce the result of any revision to the statements made herein except to the extent that they would be required to do so under applicable law or regulation. To the extent permitted by law, no responsibility or liability whatsoever is accepted by the Company or its investee companies or any of such persons' directors, officers, employees or affiliates or any other person for any loss howsoever arising, directly or indirectly, from any use of this Presentation or such information or opinions

contained herein or otherwise arising in connection herewith. Except where otherwise indicated herein, the information provided in this Presentation is based on matters as they exist as of the date of preparation and not as of any future date.

Certain statements included in this Presentation contain forward- looking information concerning the Company's and its investee companies' strategy, operations, financial performance or condition, outlook, growth opportunities or circumstances in the sectors or markets in which the Company and its investee companies operate. By their nature, forward-looking statements involve uncertainty because they depend on future circumstances, and relate to events, not all of which are within the Company's or its investee companies' control or can be predicted by the Company or by its investee companies. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Actual results could differ materially from those set out in the forward-looking statements. The forward-looking statements made in this Presentation relate only to events as of the date on which the statements are made. Nothing in this Presentation should be construed as a profit forecast and no part of these results constitutes, or shall be taken to constitute, an invitation or inducement to invest in the Company, and must not be relied upon in any way in connection with any investment decision. The Company expressly disclaim any obligation or undertaking to update or revise any forward-looking statement.

Poseida announced a strategic collaboration with Roche to research and develop allogeneic CAR-T products directed to haematologic malignancies. Total potential payments of up to $6 billion payable to Poseida.

Poseida advanced its first two allogeneic CAR-T programmes into Phase 1 clinical trials.

FDA approval of Vivjoa ® (Oteseconazole) by Viamet's successor Mycovia for the treatment of recurrent vulvovaginal candidiasis in females who are not of reproductive potential.

Immunocore's lead product candidate KIMMTRAK® is now approved in 30 countries for the treatment of metastatic uveal melanoma and generated $46 million of revenue during H1 2022.

Divested of 380k Immunocore shares generating proceeds of $20.6 million, having acquired 128k shares for total consideration of $3.7 million in December 2021 & January 2022.

Significant extension to cash runways of Immunocore & Poseida having executed equity raises alongside other positive business and non-dilutivecapital progress.